Last reviewed · How we verify
SPN-812 (600mg, QD)
SPN-812 is a selective norepinephrine reuptake inhibitor that increases norepinephrine availability in the central nervous system to improve attention and executive function.
SPN-812 is a selective norepinephrine reuptake inhibitor that increases norepinephrine availability in the central nervous system to improve attention and executive function. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
At a glance
| Generic name | SPN-812 (600mg, QD) |
|---|---|
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Drug class | Selective norepinephrine reuptake inhibitor (NRI) |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
SPN-812 selectively inhibits the norepinephrine transporter, preventing reuptake of norepinephrine at the synaptic cleft. This increases norepinephrine concentration in brain regions associated with attention, impulse control, and executive function. The drug is designed to treat attention-deficit/hyperactivity disorder (ADHD) with a mechanism distinct from traditional stimulants.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
Common side effects
- Decreased appetite
- Insomnia
- Headache
- Nausea
- Increased blood pressure
- Increased heart rate
Key clinical trials
- Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women (PHASE4)
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPN-812 (600mg, QD) CI brief — competitive landscape report
- SPN-812 (600mg, QD) updates RSS · CI watch RSS
- Supernus Pharmaceuticals, Inc. portfolio CI